Home Cart Sign in  
Chemical Structure| 56396-35-1 Chemical Structure| 56396-35-1

Structure of UK-5099
CAS No.: 56396-35-1

Chemical Structure| 56396-35-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

UK-5099 is a potent is MPC (mitochondrial pyruvate carrier) inhibitor with IC50 value of 50 nM.

Synonyms: PF-1005023

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of UK-5099

CAS No. :56396-35-1
Formula : C18H12N2O2
M.W : 288.30
SMILES Code : O=C(O)/C(C#N)=C/C1=CN(C2=CC=CC=C2)C3=C1C=CC=C3
Synonyms :
PF-1005023
MDL No. :MFCD19443867
InChI Key :BIZNHCWFGNKBBZ-JLHYYAGUSA-N
Pubchem ID :6438504

Safety of UK-5099

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302+H312-H315-H318-H411
Precautionary Statements:P264-P270-P273-P280-P301+P312+P330-P302+P352+P312-P305+P351+P338+P310-P332+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Lgr5-EGFP+ cells 10 µM 16 hours UK-5099 treatment significantly increased the percentage of GFP positive cells, indicating that MPC inhibition enhances stem cell function. Nat Cell Biol. 2017 Sep;19(9):1027-1036.
T315I-Bcr-Abl-32D cells 25 µM 16 hours UK-5099 treatment reduced GSH levels in T315I-Bcr-Abl cells and induced replication stress, making these cells more sensitive to JMF4073. Commun Biol. 2024 Jul 10;7(1):843.
4T1 cells 10 µM 24 hours Exposure to UK-5099 induced a decrease in extracellular pH and oxygen consumption rate (OCR) Free Radic Biol Med. 2024 Mar;213:11-18.
MCF10A cells 10 µM 24-30 hours To evaluate the ability of analogues to promote cellular lactate production, results showed that several analogues significantly increased lactate production rate. J Med Chem. 2021 Feb 25;64(4):2046-2063.
Human T cells 10 µM 3 hours To assess the cellular target engagement selectivity of UK-5099 for MPC2, showing sub-μM IC50 values for selective MPC2 engagement Angew Chem Int Ed Engl. 2020 Mar 2;59(10):3896-3899.
MDA-MB-231 cells 10 µM 30 minutes To assess the importance of mitochondrial pyruvate metabolism in MDA-MB-231 cells, results showed that UK-5099 significantly reduced mitochondrial respiration in persistent cells. Neoplasia. 2023 Dec;46:100949.
HCT116 cells 3 mM 40 minutes UK5099 treatment blocked the generation of all observed metabolites as well as the consumption of pyruvate, indicating that these metabolites were produced by mitochondrial enzymes in intact mitochondria. Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):4152-4157.
H661 20 µM 48 hours The combination of UK-5099 and Syrosingopine significantly inhibited the proliferation of NSCLC cells and induced cell cycle arrest and apoptosis. Cell Death Dis. 2024 Jun 19;15(6):431.
PC-9 20 µM 48 hours The combination of UK-5099 and Syrosingopine significantly inhibited the proliferation of NSCLC cells and induced cell cycle arrest and apoptosis. Cell Death Dis. 2024 Jun 19;15(6):431.
PDAC PDOs (pancreatic ductal adenocarcinoma patient-derived organoids) 5 µM 48 hours To investigate the effect of UK-5099 on the metabolic activity of PDAC PDOs. Results showed that UK-5099 treatment increased glycolytic activity in basal-like tumor PDOs and reduced maximal respiration, indicating that basal-like tumor PDOs are more sensitive to MPC1 inhibition. Cancer Metab. 2024 Oct 3;12(1):28.
3T3L1 adipocytes 5 µM 6 hours Treatment with UK5099 led to a ~50% reduction in pyruvate incorporation into the total lipid pool, indicating that UK5099 inhibits the function of the mitochondrial pyruvate carrier (MPC), thereby affecting lipid synthesis in adipocytes. Mol Metab. 2024 Oct;88:102005.
Raji cells 50 µM 72 hours Blockade of pyruvate mitochondrial transport, enhancing the efficacy of AZD3965, leading to increased cell death Cancer Res. 2017 Nov 1;77(21):5913-5924.
Hut78 cells 50 µM 72 hours Blockade of pyruvate mitochondrial transport, enhancing the anti-proliferative effects of AZD3965, increasing cell death Cancer Res. 2017 Nov 1;77(21):5913-5924.
MDA-MB-231 cells 10 µM 96 hours To evaluate the effect of UK-5099 combined with chemotherapeutic drugs on cell growth, results showed that UK-5099 synergistically inhibited the growth of persistent cells with chemotherapeutic drugs. Neoplasia. 2023 Dec;46:100949.
Human colon crypts 10 µM UK-5099 treatment promoted human colon organoid colony formation and growth. Nat Cell Biol. 2017 Sep;19(9):1027-1036.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C3H/HeNCrNarl mice T315I-Bcr-Abl-32D cell-induced leukemia model Intraperitoneal injection 10 mg/kg Every 24 hours for 14 days UK-5099 monotherapy did not significantly affect the survival of T315I leukemia mice, but combination therapy with JMF4073 significantly prolonged survival and reduced the burden of leukemia cells. Commun Biol. 2024 Jul 10;7(1):843.
Mice Patient-derived xenograft tumor model Oral 10 mg/kg twice daily or 100 mg/kg/day daily Daily treatment for 3 weeks UK-5099 slowed the growth of patient-derived xenograft (PDX) tumors in mice without severe loss of animal body weight EBioMedicine. 2017 May;19:31-38
C57BL/6J mice Hair loss model Topical administration 20 μM Every other day for 3 weeks To evaluate the ability of analogues to promote hair growth in mice, results showed that several analogues significantly accelerated hair growth. J Med Chem. 2021 Feb 25;64(4):2046-2063.
C57BL/6J animals C57BL/6J mice Topical administration 20μM 48 hours Topical treatment with UK-5099 accelerated the activation of hair follicle stem cells (HFSCs) and the hair cycle, and increased lactate levels in HFSCs. Nat Cell Biol. 2017 Sep;19(9):1017-1026
BALB/cAnNRj mice 4T1 breast cancer model Intraperitoneal injection 3 mg/kg Once daily for 4 days UK-5099 treatment induced a significant decrease in tumor pH, but no significant change in tumor oxygenation was observed Free Radic Biol Med. 2024 Mar;213:11-18.
Balb/c Nude mice Subcutaneous tumor model Intraperitoneal injection 3 mg/kg Continuously for 14 days The combination of UK-5099 and Syrosingopine significantly inhibited the growth of subcutaneous tumors without significant toxic side effects. Cell Death Dis. 2024 Jun 19;15(6):431.
BALB/c JNRj mice 4T1 breast cancer model Intraperitoneal injection 3 mg/kg Daily for four days To evaluate the impact of MPC inhibitor UK-5099 on tumor extracellular pH, results showed a significant decrease in tumor pHe of 0.22 units Cancers (Basel). 2021 Aug 25;13(17):4278

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.47mL

0.69mL

0.35mL

17.34mL

3.47mL

1.73mL

34.69mL

6.94mL

3.47mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Zhong Y, Li X, et al. Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. Oncotarget. 2015 Nov 10;6(35):37758-69.

[2]Hinoi E, Takarada T, et al. A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35.

[3]Bor Luen Tang. Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection. Brain Sci. 2019 Sep 18;9(9):238.

[4]Claire L Bensard ,et al. Regulation of Tumor Initiation by the Mitochondrial Pyruvate Carrier. Cell Metab. 2020 Feb 4;31(2):284-300.e7.

[5] Halestrap AP. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem J. 1975 April; 148(1): 85-96.

[6] Wiemer EA, et al. The inhibition of pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei and its metabolic implications. Biochem J. 1995 Dec 1;312 ( Pt 2):479-84.

[7]Hinoi E, et al. A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35. Epub 2006 Jun 9.

[8]Patterson JN, et al. Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated secretion. J Biol Chem. 2014 May 9;289(19):13335-46.

[9]Zhong Y, et al. Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. Oncotarget. 2015 Nov 10;6(35):37758-69.

 

Historical Records

Categories